Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hepatitis

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...

Viral Hepatitis I: Introduction

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...

Inhibitors of Viral Protein Synthesis

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Cystic Fibrosis: Management

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Role of viral and host factors in determining the outcome of HBV-associated acute liver failure.

Journal of translational medicine·2026

Same author

Comparison of LDH activity and LDH-M to predict death in patients with acetaminophen-induced acute liver failure.

EXCLI journal·2026

Same author

Identification of Genetic Risk Factors Associated With Herbal and Dietary Supplement-Induced Acute Liver Failure Using Whole Exome Sequencing Analysis.

Gastro hep advances·2025

Same author

Autoantibodies neutralizing type I IFNs in patients with fulminant herpes simplex virus hepatitis.

The Journal of experimental medicine·2025

Same author

The DILI-Inpt Prognostic Score to Identify Hospitalized Idiosyncratic DILI Patients at Risk for Adverse Outcomes.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2025

Same author

The endothelial growth factor angiopoietin-2 is an accurate prognostic biomarker in patients with acetaminophen-induced acute liver failure.

Toxicological sciences : an official journal of the Society of Toxicology·2025

Search research articles

Related Experiment Video

Updated: May 12, 2026

A Protocol for Analyzing Hepatitis C Virus Replication

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Hepatitis C virus therapy update 2013.

Lisa C Casey¹, William M Lee

¹Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center Dallas, Texas 75390-8887, USA.

Current Opinion in Gastroenterology

|April 9, 2013

Summary

This summary is machine-generated.

New direct-acting antiviral (DAA) therapies have transformed hepatitis C virus (HCV) treatment for genotype 1, improving outcomes. Further research is needed for patients with treatment failure and comorbidities, with hope for interferon-free regimens.

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Related Experiment Videos

Last Updated: May 12, 2026

A Protocol for Analyzing Hepatitis C Virus Replication

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Area of Science:

Hepatology
Virology
Pharmacology

Background:

Hepatitis C virus (HCV) infection remains a significant global health concern.
Treatment of HCV has evolved significantly, particularly for genotype 1.
Advances in antiviral therapies have led to improved patient outcomes.

Purpose of the Study:

To review recent literature on hepatitis C virus (HCV) therapy up to January 2013.
To discuss current HCV treatment strategies and emerging therapeutic targets.
To provide insights into the future of HCV treatment.

Main Methods:

Literature review of recent studies on HCV therapy.
Analysis of current treatment regimens, including direct-acting antivirals (DAAs).
Exploration of new drug targets and combination therapies.

Main Results:

Boceprevir and telaprevir-based triple therapy revolutionized HCV treatment for genotype 1.
Development of new DAAs and exploration of novel antiviral targets are ongoing.
Emergence of new combination regimens and hope for interferon-free treatments.

Conclusions:

HCV genotype 1 treatment standards dramatically changed with DAA approvals in 2011.
Improved response rates and treatment durations observed, but limitations persist.
Need for better therapies for treatment-experienced patients, those with comorbidities, and to mitigate side effects; interferon-free regimens offer future hope.